
The Weekly Roundup: September 22-26
Key Takeaways
- Nonsteroidal topicals are increasingly favored for challenging atopic dermatitis cases, offering new treatment options.
- Collaborative efforts between allergists and dermatologists are crucial for effective chronic spontaneous urticaria management.
In case you missed it, this week we had news about upadacitinib's phase 3 efficacy in alopecia, APG777 as a potential breakthrough in AD, the latest conference insights, and more.
To stay up-to-date with the latest dermatology news, sign up to receive our
Nonsteroidal Topicals Gain Favor in Challenging AD Cases
Rebecca Smith, MD, recently led a Dermatology Times Case-Based Roundtable event on complex cases in atopic dermatitis.
Cracking the Code of Chronic Spontaneous Urticaria: Evolving Care by Allergists and Dermatologists
Based on the diagnosis and treatment challenges of CSU, it’s crucial for allergists and dermatologists to work together toward an effective approach based on the latest evidence.
EADV 2025: Full Congress Recap
Explore groundbreaking research and insights from the EADV Congress 2025, highlighting advancements in dermatology treatments and patient care.
Roundtable Explores Real-World Use of Ruxolitinib and Emerging Systemic Therapies for Vitiligo
Todd Schlesinger, MD, FAAD, FASMS, moderated an engaging discussion with colleagues to discuss complex vitiligo cases during a Dermatology Times Case-Based Roundtable event.
Guttman-Yassky Discusses APG777 as a Potential Breakthrough in AD
By targeting IL-13, APG777 may allow for less frequent dosing compared to existing biologics.
Research-Inspired Tips From DERM 2025
Explore cutting-edge insights from DERM 2025, focusing on innovative treatments and emerging research in dermatology for improved patient care.
BMS Expands Patient Options With Direct-to-Patient Platform
Bristol Myers Squibb expands direct-to-patient pricing for deucravacitinib and apixaban, enhancing access and affordability for patients in need.
Apex Skin Expands Access and Representation in Dermatology Research
Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, shares how Apex Skin’s multi-site model advances clinical trial access, diversity, and execution.
The Power of Peer Learning: How NPs and PAs Are Key to the Future of Dermatology
As we celebrate National APP Week, Melodie Young, MSN, A/GNP-C, highlights the evolution of dermatology NPs and PAs, emphasizing their vital role in patient care and ongoing professional development.
Derm Dispatch: Unpacking Topical Steroid Withdrawal
This episode explores the controversy and lack of clear diagnostic criteria for TSW.
Technology, Advocacy, and Peer Support: How PAs and NPs Are Shaping Modern Dermatology
Explore how dermatology PAs and NPs are transforming patient care through technology, advocacy, and peer education with Andrew Baker, MBA, MPAS, PA-C.
Triveni Bio Doses First Patient in Phase 2 Trial of TRIV-509 for Atopic Dermatitis
TRIV-509 is a dual KLK5/7 inhibitor that aims to address barrier dysfunction, inflammation, and itch in moderate to severe AD.
Virginia Sybert, MD, Highlights Judicious Use of Genetic Testing
Virginia Sybert, MD, emphasizes the importance of judicious genetic testing in pediatric dermatology, advocating for collaboration to enhance patient care.
Upadacitinib Shows Strong Efficacy in Second Pivotal Phase 3 Study for Severe Alopecia Areata
Upadacitinib shows promising results in treating severe alopecia areata, achieving significant hair regrowth and setting new efficacy standards in therapy.
Closing the Gap: Why Rural Dermatology Access Must Be a Priority
Rural patients face critical delays in dermatology care, highlighting the urgent need for expanded access and support for NPs and PAs in underserved areas.
Maui Derm NP+PA Fall 2025: Full Conference Recap
Explore the latest advancements and expert insights from the Maui Derm NP+PA Fall 2025 conference in Nashville, Tennessee.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


















